163 related articles for article (PubMed ID: 35691988)
1. Hematologic malignancies following immune checkpoint inhibition for solid tumors.
van Eijs MJM; van der Wagen LE; Mous R; Leguit RJ; van de Corput L; van Lindert ASR; Suelmann BBM; Kamphuis AM; Nierkens S; Suijkerbuijk KPM
Cancer Immunol Immunother; 2023 Jan; 72(1):249-255. PubMed ID: 35691988
[TBL] [Abstract][Full Text] [Related]
2. Targeting immune checkpoints in hematological malignancies.
Salik B; Smyth MJ; Nakamura K
J Hematol Oncol; 2020 Aug; 13(1):111. PubMed ID: 32787882
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic epigenetics: an emerging clinical approach to hematologic malignancies.
Clin Adv Hematol Oncol; 2005 Mar; 3(3 Suppl 1):1-10; quiz 11-2. PubMed ID: 21438190
[No Abstract] [Full Text] [Related]
4. Acute myeloid leukemia and myelodysplastic syndrome associated with a combination of immune checkpoint inhibitor and platinum-based chemotherapy.
Nakatsuru K; Tsubouchi K; Hirahata M; Nakashima T; Takahata Y; Okamatsu Y; Shiraishi Y; Okamoto I; Harada T
Thorac Cancer; 2023 Aug; 14(22):2225-2228. PubMed ID: 37337950
[TBL] [Abstract][Full Text] [Related]
5. Immune Checkpoint Inhibition in Acute Myeloid Leukemia and Myelodysplastic Syndromes.
Abaza Y; Zeidan AM
Cells; 2022 Jul; 11(14):. PubMed ID: 35883692
[TBL] [Abstract][Full Text] [Related]
6. Incidence and Bayesian Mapping of Myeloid Hematologic Malignancies in Sardinia, Italy.
Broccia G; Carter J; Ozsin-Ozler C; De Matteis S; Cocco P
Cancer Control; 2023; 30():10732748231202906. PubMed ID: 37877513
[TBL] [Abstract][Full Text] [Related]
7. Programmed cell death-1 pathway inhibition in myeloid malignancies: implications for myeloproliferative neoplasms.
Choi DC; Tremblay D; Iancu-Rubin C; Mascarenhas J
Ann Hematol; 2017 Jun; 96(6):919-927. PubMed ID: 28062906
[TBL] [Abstract][Full Text] [Related]
8. Immune checkpoint-based therapy in myeloid malignancies: a promise yet to be fulfilled.
Bewersdorf JP; Stahl M; Zeidan AM
Expert Rev Anticancer Ther; 2019 May; 19(5):393-404. PubMed ID: 30887841
[TBL] [Abstract][Full Text] [Related]
9. Immune checkpoint inhibition therapy for advanced skin cancer in patients with concomitant hematological malignancy: a retrospective multicenter DeCOG study of 84 patients.
Leiter U; Loquai C; Reinhardt L; Rafei-Shamsabadi D; Gutzmer R; Kaehler K; Heinzerling L; Hassel JC; Glutsch V; Sirokay J; Schlecht N; Rübben A; Gambichler T; Schatton K; Pfoehler C; Franklin C; Terheyden P; Haferkamp S; Mohr P; Bischof L; Livingstone E; Zimmer L; Weichenthal M; Schadendorf D; Meiwes A; Keim U; Garbe C; Becker JC; Ugurel S
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33093156
[TBL] [Abstract][Full Text] [Related]
10. Future clinical implications for farnesyltransferase inhibitors in hematologic malignancies.
Kantarjian HM; Cortes JE; Rowe JM; Kurzrock R
Semin Hematol; 2002 Jul; 39(3 Suppl 2):36-8. PubMed ID: 12214292
[TBL] [Abstract][Full Text] [Related]
11. The emerging role of immune checkpoint based approaches in AML and MDS.
Boddu P; Kantarjian H; Garcia-Manero G; Allison J; Sharma P; Daver N
Leuk Lymphoma; 2018 Apr; 59(4):790-802. PubMed ID: 28679300
[TBL] [Abstract][Full Text] [Related]
12. Absence of FGFR3-TACC3 rearrangement in hematological malignancies with numerical chromosomal alteration.
Banella C; Ginevrino M; Catalano G; Fabiani E; Falconi G; Divona M; Curzi P; Panetta P; Voso MT; Noguera NI
Hematol Oncol Stem Cell Ther; 2021 Jun; 14(2):163-168. PubMed ID: 32199932
[TBL] [Abstract][Full Text] [Related]
13. Hypomethylating agents in combination with immune checkpoint inhibitors in acute myeloid leukemia and myelodysplastic syndromes.
Daver N; Boddu P; Garcia-Manero G; Yadav SS; Sharma P; Allison J; Kantarjian H
Leukemia; 2018 May; 32(5):1094-1105. PubMed ID: 29487386
[TBL] [Abstract][Full Text] [Related]
14. Population Pharmacokinetics of an Anti-PD-L1 Antibody, Durvalumab in Patients with Hematologic Malignancies.
Ogasawara K; Newhall K; Maxwell SE; Dell'Aringa J; Komashko V; Kilavuz N; Delarue R; Czuczman M; Sternas L; Rose S; Beach CL; Novick S; Zhou S; Palmisano M; Li Y
Clin Pharmacokinet; 2020 Feb; 59(2):217-227. PubMed ID: 31332669
[TBL] [Abstract][Full Text] [Related]
15. Expression patterns of costimulatory molecules on cells derived from human hematological malignancies.
Zheng Z; Takahashi M; Aoki S; Toba K; Liu A; Osman Y; Takahashi H; Tsukada N; Suzuki N; Nikkuni K; Furukawa T; Koike T; Aizawa Y
J Exp Clin Cancer Res; 1998 Sep; 17(3):251-8. PubMed ID: 9894758
[TBL] [Abstract][Full Text] [Related]
16. Randomized trials with checkpoint inhibitors in acute myeloid leukaemia and myelodysplastic syndromes: What have we learned so far and where are we heading?
Bewersdorf JP; Zeidan AM
Best Pract Res Clin Haematol; 2020 Dec; 33(4):101222. PubMed ID: 33279182
[TBL] [Abstract][Full Text] [Related]
17. Post-transplantation cyclophosphamide reduces the incidence of acute graft-versus-host disease in patients with acute myeloid leukemia/myelodysplastic syndromes who receive immune checkpoint inhibitors after allogeneic hematopoietic stem cell transplantation.
Saberian C; Abdel-Wahab N; Abudayyeh A; Rafei H; Joseph J; Rondon G; Whited L; Gruschkus S; Fa'ak F; Daher M; Knape C; Safa H; Shoukier M; Suarez-Almazor ME; Marcotulli M; Ludford K; Gulbis AM; Konopleva M; Ohanian M; Ravandi F; Garcia-Manero G; Oran B; Popat UR; Mehta R; Alousi AM; Daver N; Champlin R; Diab A; Al-Atrash G
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33637601
[TBL] [Abstract][Full Text] [Related]
18. Immune checkpoint inhibition in myeloid malignancies: Moving beyond the PD-1/PD-L1 and CTLA-4 pathways.
Bewersdorf JP; Shallis RM; Zeidan AM
Blood Rev; 2021 Jan; 45():100709. PubMed ID: 32487480
[TBL] [Abstract][Full Text] [Related]
19. The promise of macrophage directed checkpoint inhibitors in myeloid malignancies.
Swoboda DM; Sallman DA
Best Pract Res Clin Haematol; 2020 Dec; 33(4):101221. PubMed ID: 33279177
[TBL] [Abstract][Full Text] [Related]
20. Mutations of the WT1 gene in childhood nonlymphoid hematological malignancies.
Miyagawa K; Hayashi Y; Fukuda T; Mitani K; Hirai H; Kamiya K
Genes Chromosomes Cancer; 1999 Jun; 25(2):176-83. PubMed ID: 10338002
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
